文献速递心外重症与机械循环支持

胸外科医师学会Intermacs 2023年度报告:聚焦磁悬浮装置

The Society of Thoracic Surgeons Intermacs 2023 Annual Report: Focus on Magnetically Levitated Devices.
PubMed 文献 · Ann Thorac Surg · 2023-11-08

该报告描述了2013-2022十年间27,493例连续流左心室辅助装置(LVAD)患者的结果。2022年植入的2,517例初级LVAD中,2,512例(99.8%)为全磁悬浮(Mag-Lev)装置。Mag-Lev装置支持患者(n=10,920)的1年生存率为86%(对比79%和81%,P<.0001),5年生存率为64%(对比44%和44%,P<.0001),均高于当代和历史非Mag-Lev队列。

要点

  • 2022年植入的初级LVAD中99.8%为全磁悬浮装置。
  • Mag-Lev装置1年生存率86%,高于非Mag-Lev的79%和81%。
  • Mag-Lev装置5年生存率64%,高于非Mag-Lev的44%和44%。

核心结论

  • 在晚期心力衰竭真实世界大型队列中,当代Mag-Lev LVAD显著改善了短期和中期生存并减少了不良事件。

研究设计与样本

  • 该研究为胸外科医师学会Intermacs登记数据库的第14次年度报告,描述了2013-2022十年间27,493例连续流LVAD患者的结果。

主要发现

  • Mag-Lev装置支持患者(n=10,920)的1年生存率为86%,高于当代非Mag-Lev的79%和历史非Mag-Lev的81%(P<.0001)。
  • Mag-Lev装置支持患者的5年生存率为64%,高于当代非Mag-Lev的44%和历史非Mag-Lev的44%(P<.0001)。
  • 5年内免于胃肠道出血的比例Mag-Lev为72%,高于当代非Mag-Lev的60%(P<.0001)。
  • 5年内免于卒中的比例Mag-Lev为87%,高于当代非Mag-Lev的67%(P<.0001)。
  • 5年内免于装置故障/泵血栓的比例Mag-Lev为83%,高于当代非Mag-Lev的54%(P<.0001);免于装置相关感染的比例Mag-Lev为61%,非Mag-Lev为64%,无显著差异(P=.93)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 14th Annual Report from The Society of Thoracic Surgeons (STS) Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) describes outcomes of 27,493 patients with a continuous-flow left ventricular assist device (LVAD) from the past decade (2013-2022). In 2022, 2517 primary LVADs were implanted, of which 2512 (99.8%) were fully magnetically levitated (Mag-Lev) devices. This shift to nearly exclusive use of a Mag-Lev device led us to examine its outcomes compared with contemporary (2018-2022) and historical (2013-2017) non-Mag-Lev cohorts. Patients supported by a Mag-Lev device (n = 10,920) had a higher 1- and 5-year survival of 86% (vs 79% and 81%, P < .0001) and 64% (vs 44% and 44%, P < .0001), respectively, than those receiving non-Mag-Lev devices during the contemporary and historical eras. Over 5 years, freedom from gastrointestinal bleeding (72% vs 60%, P < .0001), stroke (87% vs 67%, P < .0001), and device malfunction/pump thrombus (83% vs 54%, P < .0001), but not device-related infection (61% vs 64%, P = .93), was higher with Mag-Lev devices compared with non-Mag-Lev support during the contemporary era. In this large primacy cohort of real-world patients with advanced heart failure, this report underscores marked improvements in short- and intermediate-term survival and reduction of adverse events with a contemporary Mag-Lev LVAD.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Jorde UP, Saeed O, Koehl D, et al. The Society of Thoracic Surgeons Intermacs 2023 Annual Report: Focus on Magnetically Levitated Devices. Ann Thorac Surg. 2023. PMID: 37944655. doi:10.1016/j.athoracsur.2023.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。